PortalPublikationenAntifolate pseudo-resistance due to elevated levels of thymi...

Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation.

Standard

Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation. / Simon, Marcel; Blatter, Johannes; Granzow, Christof.

in: ANTICANCER RES, Jahrgang 27, Nr. 2, 2, 2007, S. 769-773.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Simon, M, Blatter, J & Granzow, C 2007, 'Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation.', ANTICANCER RES, Jg. 27, Nr. 2, 2, S. 769-773. <http://www.ncbi.nlm.nih.gov/pubmed/17465201?dopt=Citation>

APA

Simon, M., Blatter, J., & Granzow, C. (2007). Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation. ANTICANCER RES, 27(2), 769-773. [2]. http://www.ncbi.nlm.nih.gov/pubmed/17465201?dopt=Citation

Vancouver

Simon M, Blatter J, Granzow C. Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation. ANTICANCER RES. 2007;27(2):769-773. 2.

Bibtex

@article{d5b23792a5784aa7b36ae6585b51bd46,
title = "Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation.",
abstract = "BACKGROUND: Batch variability of sera used for cell culture is of considerable experimental concern. A novel fetal calf serum product, FCS Gold, was claimed to be the first defined fetal calf serum free of batch variation. MATERIALS AND METHODS: The efficacy of methotrexate (MTX) and LY231514 (multitargeted antifolate, MTA) in CCRF-CEM cells and KB cells was compared using media supplemented with FCS Gold or conventional fetal bovine serum. RESULTS: IC50 values from tests using conventional serum corresponded to published data. FCS Gold fully protected the cells from antifolate drug cytotoxicity. Dialysis of FCS Gold restored responsiveness to antifolate drugs. Elevated levels of hypoxanthine and thymidine were present in FCS Gold. They were approximately 10-fold greater than the concentrations required to overcome growth arrest mediated by 2 microM MTX. CONCLUSION: FCS Gold or identical products, e.g. FBS Gold, should not be used in studies on antifolate drug action.",
author = "Marcel Simon and Johannes Blatter and Christof Granzow",
year = "2007",
language = "Deutsch",
volume = "27",
pages = "769--773",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

RIS

TY - JOUR

T1 - Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation.

AU - Simon, Marcel

AU - Blatter, Johannes

AU - Granzow, Christof

PY - 2007

Y1 - 2007

N2 - BACKGROUND: Batch variability of sera used for cell culture is of considerable experimental concern. A novel fetal calf serum product, FCS Gold, was claimed to be the first defined fetal calf serum free of batch variation. MATERIALS AND METHODS: The efficacy of methotrexate (MTX) and LY231514 (multitargeted antifolate, MTA) in CCRF-CEM cells and KB cells was compared using media supplemented with FCS Gold or conventional fetal bovine serum. RESULTS: IC50 values from tests using conventional serum corresponded to published data. FCS Gold fully protected the cells from antifolate drug cytotoxicity. Dialysis of FCS Gold restored responsiveness to antifolate drugs. Elevated levels of hypoxanthine and thymidine were present in FCS Gold. They were approximately 10-fold greater than the concentrations required to overcome growth arrest mediated by 2 microM MTX. CONCLUSION: FCS Gold or identical products, e.g. FBS Gold, should not be used in studies on antifolate drug action.

AB - BACKGROUND: Batch variability of sera used for cell culture is of considerable experimental concern. A novel fetal calf serum product, FCS Gold, was claimed to be the first defined fetal calf serum free of batch variation. MATERIALS AND METHODS: The efficacy of methotrexate (MTX) and LY231514 (multitargeted antifolate, MTA) in CCRF-CEM cells and KB cells was compared using media supplemented with FCS Gold or conventional fetal bovine serum. RESULTS: IC50 values from tests using conventional serum corresponded to published data. FCS Gold fully protected the cells from antifolate drug cytotoxicity. Dialysis of FCS Gold restored responsiveness to antifolate drugs. Elevated levels of hypoxanthine and thymidine were present in FCS Gold. They were approximately 10-fold greater than the concentrations required to overcome growth arrest mediated by 2 microM MTX. CONCLUSION: FCS Gold or identical products, e.g. FBS Gold, should not be used in studies on antifolate drug action.

M3 - SCORING: Zeitschriftenaufsatz

VL - 27

SP - 769

EP - 773

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 2

M1 - 2

ER -